Integrated Wealth Concepts LLC Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Integrated Wealth Concepts LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,962 shares of the biotechnology company's stock after acquiring an additional 1,230 shares during the period. Integrated Wealth Concepts LLC's holdings in United Therapeutics were worth $3,515,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wealthfront Advisers LLC increased its stake in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. grew its position in United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after purchasing an additional 32,213 shares in the last quarter. FMR LLC increased its position in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after acquiring an additional 393,777 shares during the last quarter. Geode Capital Management LLC raised its position in United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after acquiring an additional 44,277 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of United Therapeutics by 28.5% during the 4th quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock valued at $250,179,000 after buying an additional 157,363 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on UTHR shares. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $390.17.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $2.33 on Wednesday, reaching $303.09. 784,302 shares of the company's stock traded hands, compared to its average volume of 449,552. The firm has a market cap of $13.61 billion, a price-to-earnings ratio of 13.31, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $233.31 and a fifty-two week high of $417.82. The stock has a 50 day moving average price of $305.66 and a 200-day moving average price of $345.68.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company posted $6.17 EPS. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 74,500 shares of company stock worth $24,472,050. Company insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.